한글목차

본 보고서에서는 세계 신세포암 시장에 대해 조사했으며, 시장 개요와 함께 상시이 끝난 치료법, 파이프라인 동향, 전망 등의 정보를 제공합니다.

목차

주요 요약

치료 알고리즘

조사 목적

면역요법

• 출시 치료법
  • Opdivo(니볼루맙, Bristol Myers Squibb)
  • Keytruda(펨브롤리주맙, Merck & Co)
  • Bavencio(아베르맙, Merck KGaA)
  • Imfinzi(듀르발맙, AstraZeneca)

VEGF 억제제

• 출시 치료법
  • Cabometyx(카보잔티닙, Exelixis/Ipsen)
  • Lenvima/Kisplyx(렘바티닙, Eisai/Merck & Co)
  • Inlyta (액시티닙, Pfizer)
  • Fotivda(티보자닙, AVEO Oncology)
  • Sutent(수니티닙, Pfizer)
  • Votrient(파조파닙, Novartis)

기타 작용 메커니즘

• 출시 치료법
  • Welireg(벨즈티판, Merck & Co)
• 파이프라인 요법
  • Abexinostat(Xynomic Pharmaceuticals)
  • Savolitinib(AstraZeneca/HUTCHMED)
  • Epacadostat(Incyte)
• Tiragolumab(Roche)
• Zanzalintinib(Exelixis)

미래 치료 패러다임

부록

영문목차

Gain insights from leading KOLs on the latest trends in RCC treatment, including the steady use of Opdivo/Yervoy, the rising role of Keytruda, and the broad efficacy of Cabometyx. Discover how clinical trials and patient characteristics are shaping the future of RCC therapy.

Key brands covered in this report:

• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Cabometyx (cabozantinib)
• Imfinzi (durvalumab)
• Tecentriq (atezolizumab)
• Welireg (belzutifan)

Key questions answered:

• What are the preferred therapies for RCC, and what factors influence these choices?
• What is the expert consensus on approved RCC treatments like Opdivo, Keytruda, Cabometyx and Lenvima/Kisplyx?
• What are the most promising late-stage pipeline drugs or classes and other novel approaches for RCC?
• What must new pipeline products show in terms of safety and efficacy to gain regulatory approval and compete with current leaders, and what are their chances?
• How do patient characteristics (risk group, performance status, co-morbidities) influence RCC treatment decisions, and how will emerging treatments fit into these specific populations?
• Which advanced clinical trials have the greatest potential to change prescribing habits, and how could their outcomes impact future practice?
• How is the RCC treatment landscape expected to evolve for each patient category and treatment line in the coming years?

Companies:

Novartis, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Incyte, Exelixis, Ipsen, AVEO Oncology, Xynomic Pharma, Hutchmed.

Table of Contents

Executive summary

Treatment algorithm

Research objectives

Immunotherapy

• Marketed therapies
  • Opdivo (nivolumab; Bristol Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Bavencio (avelumab; Merck KGaA)
  • Imfinzi (durvalumab; AstraZeneca)

VEGF inhibitors

• Marketed therapies
  • Cabometyx (cabozantinib; Exelixis/Ipsen)
  • Lenvima/Kisplyx (lenvatinib; Eisai/Merck & Co.)
  • Inlyta (axitinib; Pfizer)
  • Fotivda (tivozanib; AVEO Oncology)
  • Sutent (sunitinib; Pfizer)
  • Votrient (pazopanib; Novartis)

Other mechanisms of action

• Marketed therapies
  • Welireg (belzutifan; Merck & Co.)
• Pipeline therapies
  • Abexinostat (Xynomic Pharmaceuticals)
  • Savolitinib (AstraZeneca/HUTCHMED)
  • Epacadostat (Incyte)
• Tiragolumab (Roche)
  • Key insights summary
• Zanzalintinib (Exelixis)
  • Key insights summary

Future treatment paradigm

• Key insights summary

Appendix

• KOL details
  • KOLs from the US
  • KOLs from Europe